Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report report published on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. […]

Leave a Reply

Your email address will not be published.

Previous post Orion Energy Systems (NASDAQ:OESX) Now Covered by Analysts at StockNews.com
Next post DLocal (NASDAQ:DLO) Raised to “Equal Weight” at Barclays